Investigational New Drugs

, Volume 33, Issue 3, pp 761–774 | Cite as

The oncolytic virus, pelareorep, as a novel anticancer agent: a review

  • Romit Chakrabarty
  • Hue Tran
  • Giovanni Selvaggi
  • Allison Hagerman
  • Brad Thompson
  • Matt CoffeyEmail author


Pelareorep (REOLYSIN®) is an investigational new drug, a proprietary formulation consisting of a live, replication-competent, naturally occurring Reovirus Type 3 Dearing strain. Through several preclinical studies it was determined that reovirus can exhibit profound cytotoxic effects on cancer cells predominantly with an activated RAS-signalling pathway. Moreover, it was discovered that reoviruses can “hitchhike” on peripheral blood mononuclear cells and dendritic cells, thereby evading neutralizing antibodies of the host immune system. Cell carriage, targeted delivery, triggering host immune response and other inherent characteristics of the reovirus led to its further advancement into cancer therapy. When injected into Sprague–Dawley rats, the viral routes of clearance, predominantly through the spleen and liver, remained consistent with earlier studies. Toxicology findings were considered incidental and not associated with pelareorep when tested in animal models. Pelareorep demonstrated a high level of homogeneity at the amino acid level and genetic stability when compared to the master and working virus banks. The drug is manufactured in a 100 L bioreactor after which it is purified and formulated for use in pre-clinical, clinical and research studies. Over the past few decades, we have witnessed a paradigm shift from conventional therapy to the conceivable use of oncolytic viruses for the treatment of cancer. This review will detail pre-clinical evidence of anticancer activity of pelareorep that has led to extensive clinical development. Several Phase I-II clinical trials have been completed or are ongoing in cancer patients on a broad spectrum of solid tumors and hematologic malignancies.


REOLYSIN® Pelareorep Reovirus Anticancer Oncolytic 



We would like to thank and acknowledge Sinead Boyle, Sarah Serl, Merle Crawford and other colleagues at Oncolytics Biotech Inc. for their help in preparing the manuscript.

Disclosure of potential conflict of interest

The preparation of this manuscript is sponsored by Oncolytics Biotech Inc. Romit Chakrabarty, Hue Tran, Allison Hagerman, Giovanni Selvaggi, Matt Coffey and Brad Thompson are employed by Oncolytics Biotech Inc. with stock options and/or stock.


  1. 1.
    Donnelly O, Harrington K, Melcher A, Pandha H (2013) Live viruses to treat cancer. J R Soc Med 106(8):310–314CrossRefPubMedGoogle Scholar
  2. 2.
    Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2(6):e24612CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Black AJ, Morris DG (2012) Clinical trials involving the oncolytic virus, reovirus: ready for prime time? Expert Rev Clin Pharmacol 5(5):517–520CrossRefPubMedGoogle Scholar
  4. 4.
    Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K (2012) Phase II trial of intravenous administration of REOLYSIN(®) (Reovirus Serotype-3-Dearing Strain) in patients with metastatic melanoma. Mol Ther 20(10):1998–2003CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Maitra R, Ghalib MH, Goel S (2012) Reovirus: a targeted therapeutic–progress and potential. Mol Cancer Res 10(12):1514–1525CrossRefPubMedGoogle Scholar
  6. 6.
    Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS (2010) REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16(22):5564–5572CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM (2014) Phase I clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 22(5):1056–1062CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ (2012) Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18(7):2080–2089CrossRefPubMedGoogle Scholar
  9. 9.
    Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S (2010) Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28(5):641–649CrossRefPubMedGoogle Scholar
  10. 10.
    Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M (2009) Reovirus-based therapy for cancer. Expert Opin Biol Ther 9(7):817–830CrossRefPubMedGoogle Scholar
  11. 11.
    Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS (2008) A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14(21):7127–7137CrossRefPubMedGoogle Scholar
  12. 12.
    Vidal L, Yap TA, White CL, Twigger K, Hingorani M, Agrawal V, Kaye SB, Harrington KJ, de Bono JS (2006) Reovirus and other oncolytic viruses for the targeted treatment of cancer. Target Oncol 1:130–150CrossRefGoogle Scholar
  13. 13.
    Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282(5392):1332–1334CrossRefPubMedGoogle Scholar
  14. 14.
    Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST (2013) Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis 4:e728. doi: 10.1038/cddis.2013.259 CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Marcato P, Shmulevitz M, Lee PW (2005) Connecting reovirus oncolysis and Ras signaling. Cell Cycle 4(4):556–559CrossRefPubMedGoogle Scholar
  16. 16.
    Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17(12):3351–3362CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Sabin AB (1959) Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 130(3386):1387–1389CrossRefPubMedGoogle Scholar
  18. 18.
    Tyler KL, Fields BN (1990) Reoviruses. In: Fields BN, Knipe DM et al (eds) Virology (2nd edition, chapter 47). Raven Press Ltd, New York, pp 1307–1328Google Scholar
  19. 19.
    Stanley NF (1961) Reovirus–a ubiquitous orphan. Med J Aust 48(2):815–818PubMedGoogle Scholar
  20. 20.
    Joklik WK (1981) Structure and function of the reovirus genome. Microbial Rev 45(4):483–501Google Scholar
  21. 21.
    Danthi P, Holm GH, Stehle T, Dermody TS (2013) Reovirus receptors, cell entry, and proapoptotic signaling. Adv Exp Med Biol 790:42–47CrossRefPubMedGoogle Scholar
  22. 22.
    Strong JE, Tang D, Lee PW (1993) Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 197(1):405–411CrossRefPubMedGoogle Scholar
  23. 23.
    Strong JE, Lee PW (1996) The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70(1):612–616PubMedCentralPubMedGoogle Scholar
  24. 24.
    Hershey JW (1991) Translational control in mammalian cells. Annu Rev Biochem 60:717–755CrossRefPubMedGoogle Scholar
  25. 25.
    Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49(17):4682–4689PubMedGoogle Scholar
  26. 26.
    Gong J, Mita MM (2014) Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells. Front Oncol 4:167. doi: 10.3389/fonc.2014.00167 PubMedCentralPubMedGoogle Scholar
  27. 27.
    Shmulevitz M, Marcato P, Lee PW (2005) Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 24(52):7720–7728CrossRefPubMedGoogle Scholar
  28. 28.
    Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15(8):1522–1530CrossRefPubMedGoogle Scholar
  29. 29.
    Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A (2008) Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180(9):6018–6026CrossRefPubMedGoogle Scholar
  30. 30.
    Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2009) Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 183(7):4312–4321CrossRefPubMedGoogle Scholar
  31. 31.
    Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15(13):4374–4381CrossRefPubMedGoogle Scholar
  32. 32.
    Pan D, Pan LZ, Hill R, Marcato P, Shmulevitz M, Vassilev LT, Lee PW (2011) Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation. Br J Cancer 105(7):1012–1022CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Pan D, Marcato P, Ahn DG, Gujar S, Pan LZ, Shmulevitz M, Lee PW (2013) Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. PLoS One 8(1):e54006CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Berger AK, Danthi P (2013) Reovirus activates a caspase-independent cell death pathway. MBio 4(3):e00178-13. doi: 10.1128/mBio. 00178-13 CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, Neri P, Pho M, Stewart D, Mansoor A, Morris DG (2012) Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 18(18):4962–4972CrossRefPubMedGoogle Scholar
  36. 36.
    Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, Neri P, Pho M, Stewart D, Mansoor A, Morris DG (2013) Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy 9(3):413–414. doi: 10.4161/auto.22867 CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Smakman N, van der Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel Rinkes IH, Kranenburg O (2006) Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 13(8):815–858CrossRefPubMedGoogle Scholar
  38. 38.
    Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. J Natl Cancer Inst 90(9):675–684CrossRefPubMedGoogle Scholar
  39. 39.
    Maitra R, Seetharam R, Tesfa L, Augustine TA, Klampfer L, Coffey MC, Mariadason JM, Goel S (2014) Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget 5(9):2807–2819PubMedCentralPubMedGoogle Scholar
  40. 40.
    Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1(8):639–649PubMedGoogle Scholar
  41. 41.
    Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer 12:368CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Ghafar MA, Anastasiadis AG, Chen MW, Burchardt M, Olsson LE, Xie H, Benson MC, Buttyan R (2003) Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 54(1):58–67CrossRefPubMedGoogle Scholar
  43. 43.
    Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL (2007) RACK1 competes with HSP90 for binding to HIF-1α and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25(2):207–217CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Saraf PG, Miller CL (2014) HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic Mammalian Orthoreovirus. Oncotarget 5(2):561–574Google Scholar
  45. 45.
    Figová K, Hraběta J, Eckschlager T (2013) Anticancer efficiency of reovirus in normoxia and hypoxia. Folia Biol (Praha) 59(2):68–75Google Scholar
  46. 46.
    Park EH, Park EH, Cho IR, Srisuttee R, Min HJ, Oh MJ, Jeong YJ, Jhun BH, Johnston RN, Lee S, Koh SS, Chung YH (2010) CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 17(5):307–314CrossRefPubMedGoogle Scholar
  47. 47.
    Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers 2014:513158. doi: 10.1155/2014/513158 CrossRefPubMedCentralPubMedGoogle Scholar
  48. 48.
    Hata Y, Etoh T, Inomata M, Shiraishi N, Nishizono A, Kitano S (2008) Efficacy of oncolytic reovirus against human breast cancer cells. Oncol Rep 19(6):1395–1398PubMedGoogle Scholar
  49. 49.
    Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, Kubota E, Mizoshita T, Tanida S, Johnston RN, Asai K, Joh T (2015) Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells. Cancer Lett 356(2):846–854CrossRefPubMedGoogle Scholar
  50. 50.
    Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, Tyler KL (2000) Reovirus-induced apoptosis is mediated by TRAIL. J Virol 74(17):8135–8139CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Dey A, Verma CS, Lane DP (2008) Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 98(1):4–8CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruine AP, Goldbohm RA, van den Brandt PA (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24(4):703–710CrossRefPubMedGoogle Scholar
  53. 53.
    Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA (2012) Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 4(138):138–147CrossRefGoogle Scholar
  54. 54.
    Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA (2013) Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 132(10):2327–2338CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Donnelly O, Vile R, Pandha H, Harrington K, Melcher A (2012) The hitchhiker’s guide to virotherapy. Oncotarget 3(8):735–736PubMedCentralPubMedGoogle Scholar
  56. 56.
    Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA (2011) Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 17(9):2767–2776CrossRefPubMedCentralPubMedGoogle Scholar
  57. 57.
    Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA (2009) Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 16(5):689–699CrossRefPubMedGoogle Scholar
  58. 58.
    Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile RG, Harrington KJ, de Bono JS, Spicer J (2014) Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res pii: clincanres.1770.2014Google Scholar
  59. 59.
    Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA (2014) Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer 134(5):1091–1101CrossRefPubMedCentralPubMedGoogle Scholar
  60. 60.
    Verdin EM, Lynn SP, Fields BN, Maratos-Flier E (1988) Uptake of reovirus serotype 1 by the lungs from the bloodstream is mediated by the viral hemagglutinin. J Virol 62(2):545–551PubMedCentralPubMedGoogle Scholar
  61. 61.
    Verdin EM, Maratos-Plier E, Kahn CR, Sodoyez JC, Sodoyez-Goffaux F, De Vos CJ, Lynn SP, Fields BN (1987) Visualization of viral clearance in the living animal. Science 236:439–442CrossRefPubMedGoogle Scholar
  62. 62.
    Chakrabarty R, Tran H, Boulay I, Moran T, Parenteau A, Tavcar R, Bigras M, Hagerman A, Serl S, Thompson B, Coffey M (2013) Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague–Dawley rats. Invest New Drug 31(6):1476–1486CrossRefGoogle Scholar
  63. 63.
    Abramczuk J, Vorbrodt A, Rubin DH, Fields BN, Koprowski H (1983) Interactions of preimplantation mouse embryos with reovirus serotypes 1 and 3. Infect Immun 42(1):301–307PubMedCentralPubMedGoogle Scholar
  64. 64.
    Kilham L, Margolis G (1973) Pathogenesis of intrauterine infections in rats due to reovirus type 3. I. Virologic studies. Lab Invest 28(5):597–604Google Scholar
  65. 65.
    Margolis G, Kilham L (1973) Pathogenesis of intrauterine infections in rats due to reovirus type 3. II. Pathologic and fluorescent antibody studies. Lab Invest 28(5):605–613Google Scholar
  66. 66.
    Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ (2004) Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic. Cancer Biol Ther 3(8):734–738CrossRefPubMedGoogle Scholar
  67. 67.
    Chakrabarty R, Tran H, Fortin Y, Yu Z, Shen SH, Kolman J, Onions D, Voyer R, Hagerman A, Serl S, Kamen A, Thompson B, Coffey M (2014) Evaluation of homogeneity and genetic stability of REOLYSIN(®) (pelareorep) by complete genome sequencing of reovirus after large scale production. Appl Microbiol Biotechnol 98(4):1763–1770CrossRefPubMedGoogle Scholar
  68. 68.
    Wiener JR, Joklik WK (1989) The sequences of the reovirus serotype 1, 2, and 3 L1 genome segments and analysis of the mode of divergence of the reovirus serotypes. Virology 169(1):194–203CrossRefPubMedGoogle Scholar
  69. 69.
    Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14(22):7358–7366CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Prestwich RJ, Ilett EJ, Steele L, Errington F (2008) The importance of the immune system in reovirus therapy. Clin Oncol 20(10):769CrossRefGoogle Scholar
  71. 71.
    Gujar SA, Marcato P, Pan D, Lee PW (2010) Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther 9(11):2924–2933CrossRefPubMedGoogle Scholar
  72. 72.
    Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, Coffey M, Selby P, Vile R, Melcher A (2011) Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer 10:20CrossRefPubMedCentralPubMedGoogle Scholar
  73. 73.
    Gujar SA, Pan DA, Marcato P, Garant KA, Lee PW (2011) Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther 19(4):797–804CrossRefPubMedCentralPubMedGoogle Scholar
  74. 74.
    Gujar S, Dielschneider R, Clements D, Helson E, Shmulevitz M, Marcato P, Pan D, Pan LZ, Ahn DG, Alawadhi A, Lee PW (2013) Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther 21(2):338–347CrossRefPubMedCentralPubMedGoogle Scholar
  75. 75.
    Gujar SA, Clements D, Lee PW (2014) Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 3(1):e27622CrossRefPubMedCentralPubMedGoogle Scholar
  76. 76.
    Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW (2014) Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer 110(1):83–93CrossRefPubMedCentralPubMedGoogle Scholar
  77. 77.
    Hall K, Scott KJ, Rose A, Desborough M, Harrington K, Pandha H, Parrish C, Vile R, Coffey M, Bowen D, Errington-Mais F, Melcher AA (2012) Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. Biores Open Access 1(1):3–15CrossRefPubMedCentralPubMedGoogle Scholar
  78. 78.
    El-Sherbiny YM, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP (2014) Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin Exp Immunol. doi: 10.1111/cei.12562 Google Scholar
  79. 79.
    Alsharifi M, Regner M, Blanden R, Lobigs M, Lee E, Koskinen A, Müllbacher A (2006) Exhaustion of type I interferon response following an acute viral infection. J Immunol 177(5):3235–3241CrossRefPubMedGoogle Scholar
  80. 80.
    Zuniga EI, Liou LY, Mack L, Mendoza M, Oldstone MB (2008) Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. Cell Host Microbe 4(4):374–386CrossRefPubMedCentralPubMedGoogle Scholar
  81. 81.
    Zaidi S, Shim K, Rajani K, Diaz R, Ilett E, Kottke T, Thompson J, Selby P, Harrington K, Pandha H, Melcher A, Coffey M, Vile R (2014) Combination therapy of reovirus and checkpoint inhibition. Poster B88 In: Tumor Immunology and Immunotherapy: A New Chapter, American Association of Cancer Research Meeting, Dec 1–4, 2014, Orlando, Florida, USA. (Accessed on 15 January 2015)
  82. 82.
    Mostafa AA, Grattan K, Lawson KA, Shi ZQ, Thirukkumaran C, Morris DG (2014) PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy. Poster A12 In: Tumor Immunology and Immunotherapy: A New Chapter, American Association of Cancer Research Meeting, Dec 1–4, 2014, Orlando, Florida, USA. (Accessed on 15 January 2015)
  83. 83.
    Lolkema MP, Arkenau H-T, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, Evans TRJ, de Bono JS (2011) A Phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17(3):581–588CrossRefPubMedGoogle Scholar
  84. 84.
    Jebar A, West E, Scott K, Thomson S, Corns R, Coffey MC, Rose A, Nuovo G, Ryan M, Errington-Mais F, Ralph C, Twelves C, Griffin S, Harrington KJ, Pandha HS, Donnely O, Selby PJ, Vile R, Short S, Melcher A (2014) Oncolytic wild-type reovirus infection in brain tumor following intravenous administration in patients. [abstract]. In: 2014 ASCO Annual Meeting; 2014 May 30 – June 03; Chicago, IL. J Clin Oncol. 32:5s(Suppl; abstract 3104)Google Scholar
  85. 85.
    Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ (2012) Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 20(5):521–528Google Scholar
  86. 86.
    Sei S, Mussio JK, Yang Q, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE (2009) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents against non-small cell lung cancer (NSCLC). Mol Cancer 8:47CrossRefPubMedCentralPubMedGoogle Scholar
  87. 87.
    Mita AC, Argiris A, Coffey M, Gill GM, Mita M (2013) A Phase 2 study of intravenous administration of REOLYSIN® (Reovirus Type 3 Dearing) in combination with paclitaxel and carboplatin in patinets with squamous cell carcinoma of the lung. [abstract]. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting, Oct 19–23, 2013, Boston, Massachusetts, USAGoogle Scholar
  88. 88.
    Phelps M, Cohn DR, O’Malley DM, Wei L, Wilkins D, Campbell A, Schaff LJ, Coffey MC, Villalona-Calero MA, Grever MR, Nuovo GJ, Zwiebel JA (2010) Reovirus replication in ovarian and peritoneal tumors after intravenous administration. [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17–21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 70(8 Suppl):Abstract nr2594Google Scholar
  89. 89.
    Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi Z-Q, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, Nishikawa S, Donnelly B, Coffey M, Trpkov K, Fonseca K, Spurrell J, Morris DG (2010) Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70(6):2435–2444CrossRefPubMedGoogle Scholar
  90. 90.
    Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PWK (2002) Reovirus oncolysis of human breast cancer. Hum Gene Ther 13(5):641–652CrossRefPubMedGoogle Scholar
  91. 91.
    Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC (2014) A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res 20(23):5946–5955CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Romit Chakrabarty
    • 1
  • Hue Tran
    • 1
  • Giovanni Selvaggi
    • 1
  • Allison Hagerman
    • 1
  • Brad Thompson
    • 1
  • Matt Coffey
    • 1
    Email author
  1. 1.Oncolytics Biotech Inc.CalgaryCanada

Personalised recommendations